New Research Sheds Light on Blood Clot Risks in Rare Inflammatory Vessel Diseases
Researchers from Monash University and leading international institutions have published significant findings in Nature Reviews Rheumatology that could transform how clinicians approach the diagnosis and treatment of systemic vasculitis – a diverse group of rare diseases that cause inflammation of the blood vessels.
The comprehensive review, led by Dr Giacomo Emmi from the Centre for Inflammatory Diseases at Monash School of Clinical Sciences, addresses a critical gap in understanding why patients with systemic vasculitis face a higher risk of developing blood clots, a complication that significantly worsens worsens outcomes and complicates diagnosis.
The research examined various forms of systemic vasculitis, including small-vessel and large-vessel vasculitis, and Behçet syndrome. Particularly noteworthy is the study's focus on newly identified genetic conditions such as DADA2 (deficiency of adenosine deaminase 2) and VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome, which exhibit similar inflammatory vessel features and carry exceptionally high blood clot risks.
The findings revealed that blood clot formation in these conditions results from complex interactions between inflammatory processes and blood coagulation abnormalities. Key mechanisms include damage to blood vessel linings and the presence of proteins that simultaneously promote inflammation and clotting - creating a dangerous cycle that can lead to serious complications.
"Our research aims to help better understand the intricate relationship between inflammation and thrombosis, not only within systemic vasculitis but also in more prevalent conditions like heart attack and stroke," said Dr Emmi. "By enhancing our understanding of these mechanisms, we hope to pave the way for innovative treatment strategies that extend beyond traditional medications, ultimately improving patient outcomes and quality of life for many."
The research advocates for treatment strategies that simultaneously address both thrombosis prevention and inflammatory response management. This dual approach is particularly important for conditions such as Behçet syndrome and DADA2, where controlling underlying inflammation is essential to manage the risk of blood clots.
The international collaboration brought together expertise from eight institutions across six countries, including the University of Florence, FAU Erlangen-Nürnberg, University of Turin, University of Adelaide, Lund University, Sechenov University (Moscow), and Istanbul University. This global partnership reflects the rare nature of these conditions and the necessity for pooled knowledge and resources to advance understanding.
Dr Emmi noted that increased awareness among healthcare professionals could lead to earlier, more accurate diagnoses, ultimately benefiting patients who may otherwise experience delayed treatment or misdiagnosis of these complex conditions.
The study represents a significant step forward in understanding the mechanisms underlying thrombotic complications in inflammatory vessel diseases, offering hope for improved diagnostic approaches and more effective, targeted treatments for patients facing these challenging conditions.
Read the full review in Nature Reviews Rheumatology.
About Monash University
Monash University is Australia’s largest university with more than 80,000 students. In the 60 years since its foundation, it has developed a reputation for world-leading high-impact research, quality teaching, and inspiring innovation.
With four campuses in Australia and a presence in Malaysia, China, India, Indonesia and Italy, it is one of the most internationalised Australian universities.
As a leading international medical research university with the largest medical faculty in Australia and integration with leading Australian teaching hospitals, we consistently rank in the top 50 universities worldwide for clinical, pre-clinical and health sciences.
For more news, visit Medicine, Nursing and Health Sciences or Monash University.
MEDIA ENQUIRIES